Theravance Biopharma, Inc.

NASDAQ•TBPH

CEO: Mr. Rick E. Winningham M.B.A.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2014-05-16

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Contact Information

901 Gateway Boulevard, South San Francisco, CA, 94080, United States

650-808-6000

www.theravance.com

Market Cap

$859.39M

P/E (TTM)

7.5

22.5

Dividend Yield

52W High

$21.03

52W Low

$8.33

52W Range

66%

Rank55Top 80.0%

2.6

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 2.6 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q1 2026 Data

Revenue

$17.70M+0.00%

4-Quarter Trend

EPS

-$0.10+0.00%

4-Quarter Trend

FCF

$73.28M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Net Income Reaches Profitability Recognized $105.9M net income in 2025, reversing prior $56.4M net loss; driven by milestone gains.

Total Revenue Jumps 67% Total revenues reached $107.5M in 2025, marking a 67% increase from $64.4M in 2024.

TRELEGY Royalty Sale Complete Recognized $75.1M net gain from TRELEGY royalty sale to GSK in June 2025; retained future milestones.

YUPELRI Net Sales Grew 12% Total YUPELRI net sales increased 12% to $266.6M in 2025; customer demand grew 7% year-over-year.

Risk Factors

Ampreloxetine Program Discontinued Phase 3 CYPRESS study failed primary endpoint; company decided to wind down entire ampreloxetine program immediately.

Workforce Reduction Implemented Restructuring reduces G&A by 60% ($70M savings); impacts approximately 50% of 90 employees immediately.

Strategic Review Distraction Risk Strategic review process uncertainty could adversely affect business, distract management, and harm personnel retention.

YUPELRI Acceptance Uncertainty Continued growth of YUPELRI sales depends on physician/payor acceptance; pricing dynamics remain challenging.

Outlook

Cost Savings Realization Expected Full run-rate cost savings of approximately $70 million expected starting Q3 2026 following organizational restructuring actions.

Focus Shifts to YUPELRI Resources realigned to commercial focus on YUPELRI; R&D function completely wound down as part of streamlining.

Future Capital Needs Uncertain Future capital needs depend on YUPELRI support, litigation, and potential licensing outcomes; current cash sufficient for twelve months.

Peer Comparison

Revenue (TTM)

VALN

$197.09M

+3.0%

GERN

$196.12M

+68.6%

DAWN

$158.18M

+20.6%

Gross Margin (Latest Quarter)

VIR

9793.1%

-54902.1pp

ATXS

100.0%

+0.0pp

GERN

96.7%

-45.2pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
TERN	$4.77B	-51.3	-20.0%	0.1%
ERAS	$3.25B	-11.5	-77.0%	10.0%
DAWN	$2.22B	-20.7	-23.4%	0.5%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

-12.3%

Growth Under Pressure

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

50%

Cash Flow Needs Attention

Deep Research

Next earnings:May 14, 2026

EPS:$0.03

Revenue:$17.78M

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data